Quant Business Cycle Fund
The scheme seeks to generate long-term capital appreciation by investing with focus on riding business cycles through allocation between sectors and stocks at different stages of business cycles.
Growthvine rating: 4/5 — ranked #41 of 186 in category.
Fund basics
| Category | Equity: Thematic |
|---|
| NAV | ₹14.97 (as of 2026-10-23) |
|---|
| AUM | ₹930 Cr |
|---|
| Expense ratio | 1.95% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Ayusha Kumbhat |
|---|
| Exit load | 1% for redemption within 15 days |
|---|
Performance & risk
| Sharpe ratio | 0.26 |
|---|
| Standard deviation | 20.75% |
|---|
| Max drawdown | −30.87% |
|---|
| Alpha | -0.59 |
|---|
| Beta | 1.2 |
|---|
Over 5 years, captured 74.4% of NIFTY Alpha 50's upside and 75.6% of its downside.
Market cap allocation
| Large cap | 44.3% |
|---|
| Mid cap | 48.6% |
|---|
| Small cap | 7.1% |
|---|
Concentration
| Top 5 holdings | 46.4% |
|---|
| Top 10 holdings | 70.8% |
|---|
| Total holdings | 17 |
|---|
Top holdings
- TREPS 01-Oct-2026 DEPO 10 — 23.1%
- Aurobindo Pharma Ltd. — 10.4%
- Piramal Finance Limited — 9.2%
- Adani Green Energy Limited — 9.1%
- Reliance Industries Ltd. — 9.0%
- INDUS TOWERS LIMITED — 8.7%
- LG Electronics India Limited — 5.7%
- Adani Enterprises Ltd. — 5.1%
- Samvardhana Motherson International Limited — 4.8%
- Lloyds Metals and Energy Limited — 4.7%
Top sectors
- Derivatives — 19.8%
- Energy — 12.5%
- Pharma & Biotech — 12.1%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −4.2% | Q2 | #57 of 167 |
| 2025 | −6.5% | Q4 (Bottom) | #125 of 132 |
| 2024 | 19.2% | Q3 | #50 of 86 |